Eyeworld Supplements

THERAPEUTIC POTENTIAL OF REGENER-EYES ® OPHTHALMIC SOLUTION IN THE TREATMENT OF DRY EYE DISEASE 7 | WHITE PAPER | JULY 2021 epithelial cell proliferation, and prevent neural injury. Accordingly, significantly improved visual acuity, relieved ocular pain and complete heal- ing of corneal epithelial defects were noticed in a Regener-Eyes ® -treated patient with Sjögren's syn- drome. Similarly, 4 weeks of Regener-Eyes ® -based therapy remarkably improved visual acuity and significantly decreased ocular pain in a 26-year- old female who suffered from severe DED and ep- ithelial basement membrane dystrophy (EBMD) with recurrent corneal erosion syndrome (RCES). Importantly, no recurrence of RCES symptoms were observed in this Regener-Eyes ® -treated pa- tient during a follow-up of 4 months, suggesting beneficial effects of Regener-Eyes ® in the repair and regeneration of injured corneal epithelial cells. Conclusions Regener-Eyes ® drops are a topical therapy for DED; they are an engineered biological product. The drops contain a large number of anti-in- flammatory and trophic factors that attenuate the detrimental immune response in the eye and protect the epithelial cells of the ocular surface from injury and inflammation. 1,9,12–13,15 Topical administration of Regener-Eyes ® may suppress ongoing ocular inflammation, may improve meibomian gland function, and may enhance the restoration of the ocular surface barrier in DED patients, without causing treatment-re- lated adverse events. 1,13 Due to its potent im- munosuppressive and regenerative properties, Regener-Eyes ® should be considered as a power- ful new therapeutic option in the management of DED. tortuosity. 13 The morphology of the meibo- mian glands was significantly improved after 3 weeks of Regener-Eyes ® therapy showing the hypo-illuminescent grape-like clusters. Similarly, hyper-illuminescent ducts tarsus indicated ben- eficial effects of Regener-Eyes ® in restoration of meibomian gland and ducts morphology. 13 Ad- ditionally, Regener-Eyes ® significantly improved DED-related symptoms in this MGD patient. 13 Before topical application of Regener-Eyes ® , an MGD patient reported foreign body sensation and pain in the eyes, which were accompanied with grittiness, soreness, irritation, burning, and eye fatigue. Importantly, none of these DED-related symptoms were reported by the MGD patient af- ter 3 weeks of Regener-Eyes ® therapy. 13 Signifi- cantly improved tear film breakup time (TBUT) was noticed 3 weeks after Regener-Eyes ® -based treatment, indicating restoration of meibomian gland function. 13 Complications such as ocular pain, persistent bleeding, and infections were not observed during or after the administra- tion of Regener-Eyes ® . This MGD patient did not report any adverse effects related to the Regener-Eyes ® -based therapy, confirming that Regener-Eyes ® is well tolerated and safe for topi- cal application. 13 Approximately 1 of 10 patients suffering from dry eye has underlying Sjögren's syndrome, an autoimmune disease characterized by immune cell-dependent destruction of lacrimal and sal- ivary glands, ocular discomfort, and visual dys- function. 21 Since Sjögren's syndrome-related dry eye is a progressive inflammatory condi- tion, it may lead to corneal perforation, uveitis, scleritis, retinal vasculitis, and optic neuritis. Regener-Eyes ® contains immunoregulatory, tro- phic and neuroprotective factors that could atten- uate ongoing inflammation in the eye, promote

• Cover